亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy—A secondary analysis of the TRACE-III randomized trial

医学 特奈特普酶 随机对照试验 心脏病学 缺血性中风 内科学 冲程(发动机) 溶栓 心肌梗塞 二级预防 组织纤溶酶原激活剂 梗塞 纤溶剂 缺血 死亡率 临床试验 脑缺血 脑梗塞 梅德林
作者
Liyuan Wang,Li Zhou,Jinfeng Yin,Aoming Jin,Bruce C.V. Campbell,Marc Fisher,Lee H. Schwamm,Mark William Parsons,Xia Meng,Chunmiao Duan,Lixia Zong,Wanxing Ye,Fengyuan Che,Lihua Wang,Hongguo Dai,Hao Wang,Ziran Wang,Manjun Hao,Zhixin Cao,Shuangzhe Wu
出处
期刊:International Journal of Stroke [SAGE Publishing]
卷期号:: 17474930261443408-17474930261443408
标识
DOI:10.1177/17474930261443408
摘要

BACKGROUND: We aimed to explore whether the benefits of tenecteplase within 4.5 to 24 h would be modified by the infarct growth rate (IGR). METHODS: This study is a secondary analysis of the Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III (TRACE-III) trial, a Phase 3, multicenter, prospective, open-label, randomized, blinded-outcome-assessment trial. In the TRACE-III trial, patients with large-vessel occlusion at 4.5 to 24 h without thrombectomy were enrolled at 58 centers in China and randomly assigned to receive 0.25 mg/kg tenecteplase or standard medical treatment. Of these, patients with witnessed stroke onset time were analyzed. The IGR was calculated as baseline ischemic core volume divided by time since onset. The primary outcome was the modified Rankin Scale (mRS) 0-1 at 90 days. The treatment effect of tenecteplase versus standard medical treatment was assessed in two groups based on the median IGR cut point. A multiplicative interaction term for IGR*treatment was used to test for effect modification. RESULTS: In 292 eligible patients, the median IGR was 1.4 ml/h. A total of 146 patients with IGR < 1.4 ml/h were classified as ultraslow IGR (Tenecteplase, 70; Standard medical treatment, 76), and 146 patients with IGR ⩾ 1.4 ml/h were classified as slow IGR (Tenecteplase, 73; Standard medical treatment, 73). The rate of no disability (mRS ⩽ 1) was significantly increased with tenecteplase in slow progressors (34.2% vs 15.1%; OR = 2.94, 95% CI 1.32 to 6.55; P = 0.009). The functional status was similar in ultraslow progressors (mRS 0-1: 37.1% vs 35.5%; OR = 1.07, 95% CI 0.55 to 2.11; P = 0.84). A P value for the interaction between IGR and treatment was 0.06. The incidence of sICH and mortality did not differ significantly between the two treatment regimens in the IGR groups. CONCLUSION: Patients with late-window ischemic stroke who are not eligible for endovascular thrombectomy may derive greater benefit from tenecteplase compared with standard medical treatment among those with relatively faster infarct growth, although this finding should be considered exploratory.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
殷勤的亦竹完成签到,获得积分10
8秒前
能干的荆完成签到 ,获得积分10
10秒前
11秒前
忧虑的四娘完成签到,获得积分10
12秒前
内卷带师完成签到 ,获得积分10
15秒前
科研通AI6.4的应助被辛勤的乌采纳,获得50
18秒前
尊敬康乃馨完成签到,获得积分10
26秒前
灵剑山发布了新的文献求助10
32秒前
33秒前
37秒前
科研通AI6.4的应助被灵剑山采纳,获得10
43秒前
KKIII发布了新的文献求助10
44秒前
44秒前
45秒前
louis861933完成签到,获得积分10
51秒前
邓润杰发布了新的文献求助30
51秒前
可爱的函函的应助被KKIII采纳,获得10
55秒前
单身的涫完成签到,获得积分10
58秒前
小张完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
赵志博发布了新的文献求助10
1分钟前
清秀的傲云完成签到,获得积分10
1分钟前
Hello的应助被Louisa采纳,获得10
1分钟前
Maestro_S的应助被迅速的天玉采纳,获得10
1分钟前
1分钟前
11JIN完成签到 ,获得积分10
1分钟前
忧心的棒球完成签到,获得积分10
1分钟前
fff完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
桐桐的应助被Louisa采纳,获得10
1分钟前
KKIII发布了新的文献求助10
1分钟前
1分钟前
芒果完成签到 ,获得积分10
1分钟前
zmy完成签到 ,获得积分10
1分钟前
现代的擎苍发布了新的文献求助100
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780029
捐赠科研通 7764837
什么是DOI,文献DOI怎么找? 3431499
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476579